Drug Search Results
More Filters [+]


Alternative Names: PRT-3645, PRT3645, PRT 3645
Latest Update: 2024-06-03
Latest Update Note: News Article

Product Description

PRT3645 is a highly potent, selective and brain penetrant CDK4/6 inhibitor that demonstrated greater than 10x brain penetration compared to approved CDK4/6 agents in preclinical models.  (Sourced from: https://preludetx.com/science/discovery-engine/prt3645-cdk4-6/)

Mechanisms of Action: CDK Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Prelude Therapeutics
Company Location: WILMINGTON DE 19803
Company CEO: Krishna Vaddi
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PRT-3645

Countries in Clinic: Singapore, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Breast Cancer|Endometrial Cancer|Glioblastoma|Head and Neck Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Sarcoma|Squamous Cell Carcinoma



Trial Status


Primary Completion Date

Probability of Success



Active, not recruiting

Glioblastoma|Endometrial Cancer|Breast Cancer|Sarcoma|Mesothelioma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer



Recent News Events